Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics Inc (VTGN) is a clinical-stage biopharmaceutical company pioneering neuroscience-focused treatments through innovative stem cell technology. This page provides investors and industry professionals with essential updates on the company’s progress, including press releases, clinical trial milestones, and strategic developments.
Access real-time information on VTGN’s advancements in predictive toxicology, drug metabolism screening, and neuropsychiatric therapies. Our curated news collection ensures you stay informed about regulatory submissions, partnership announcements, and financial disclosures without needing to track multiple sources.
Key updates include progress in stem cell-derived bioassay systems, FDA communications regarding therapeutic candidates, and insights into the company’s unique approach to in vitro testing. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to VTGN’s latest developments. Check back regularly for authoritative reporting on advancements in neuroscience and biotechnology that could shape the future of drug discovery.
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company focusing on psychiatric and neurological disorders, will report its fiscal year 2024 financial results on June 11, 2024.
The announcement will be made through a conference call and webcast at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). During the call, Vistagen will provide a detailed update on its corporate activities and financial performance for the fiscal year ending March 31, 2024.
Participants can join the call using the toll-free number 1-877-407-9716 in the US, or 1-201-493-6779 internationally, with the Conference ID: 13746589. A replay will be available shortly after the call ends.
Vistagen, a late clinical-stage biopharmaceutical company focused on innovative therapies for psychiatric and neurological disorders, announced its participation in the Jefferies Global Healthcare Conference on June 5-6, 2024, in New York City.
CEO Shawn Singh will present a fireside chat on June 6 at 11:00 a.m. EST, with a webcast available on Vistagen's website. Interested investors can arrange one-on-one meetings through their Jefferies representative.
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, announced it will present posters at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference from May 28-31, 2024, in Miami Beach, Florida.
The presentations will focus on fasedienol (PH94B) for social anxiety disorder (SAD) and itruvone (PH10) for major depressive disorder (MDD). The fasedienol poster, titled 'Results from the PALISADE-2 Phase 3 Trial,' will be presented on May 29, 2024, at 11:15 a.m. ET. The itruvone poster, titled 'Brain and Peripheral Tissue Distribution of Intranasal Radiolabeled Itruvone (PH10) in Laboratory Rats,' will also be presented on May 29, 2024, at 11:15 a.m. ET.
Both posters will be available on Vistagen's website from June 3, 2024.
Vistagen (Nasdaq: VTGN) will be presenting at the 2024 RBC Capital Markets Global Healthcare Conference in New York City. CEO Shawn Singh will participate in a fireside chat on May 15. Investors can arrange one-on-one meetings through their RBC representative.